KR20230095983A - Gm-csf 길항제를 사용한 암의 치료 - Google Patents

Gm-csf 길항제를 사용한 암의 치료 Download PDF

Info

Publication number
KR20230095983A
KR20230095983A KR1020237015960A KR20237015960A KR20230095983A KR 20230095983 A KR20230095983 A KR 20230095983A KR 1020237015960 A KR1020237015960 A KR 1020237015960A KR 20237015960 A KR20237015960 A KR 20237015960A KR 20230095983 A KR20230095983 A KR 20230095983A
Authority
KR
South Korea
Prior art keywords
antibody
cancer
csf
patient
csf antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237015960A
Other languages
English (en)
Korean (ko)
Inventor
조 피렐로
에벤 테사리
루이스 카르바잘
아날리사 드안드레아
Original Assignee
키닉사 파마슈티컬스, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 키닉사 파마슈티컬스, 리미티드 filed Critical 키닉사 파마슈티컬스, 리미티드
Publication of KR20230095983A publication Critical patent/KR20230095983A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
KR1020237015960A 2020-10-26 2021-10-26 Gm-csf 길항제를 사용한 암의 치료 Pending KR20230095983A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063105773P 2020-10-26 2020-10-26
US63/105,773 2020-10-26
US202063120319P 2020-12-02 2020-12-02
US63/120,319 2020-12-02
US202163242849P 2021-09-10 2021-09-10
US63/242,849 2021-09-10
PCT/US2021/056700 WO2022093855A1 (en) 2020-10-26 2021-10-26 Treatment of cancers with gm-csf antagonists

Publications (1)

Publication Number Publication Date
KR20230095983A true KR20230095983A (ko) 2023-06-29

Family

ID=78820846

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015960A Pending KR20230095983A (ko) 2020-10-26 2021-10-26 Gm-csf 길항제를 사용한 암의 치료

Country Status (6)

Country Link
US (1) US20220184179A1 (https=)
EP (1) EP4232162A1 (https=)
JP (1) JP2023546657A (https=)
KR (1) KR20230095983A (https=)
AU (1) AU2021372454A1 (https=)
WO (1) WO2022093855A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240309079A1 (en) * 2023-03-14 2024-09-19 Taran Therapeutics, Inc. Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
WO2025096692A2 (en) * 2023-11-01 2025-05-08 Taran Therapeutics, Inc. Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4943044B2 (ja) 2005-07-20 2012-05-30 リンテック株式会社 粘着シート
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013026059A1 (en) * 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
CA2851322C (en) 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
CN106456761A (zh) 2014-05-19 2017-02-22 免疫医疗有限公司 对类风湿关节炎的治疗
EP3786293A1 (en) 2015-06-12 2021-03-03 AxioMx, Inc. Methods and compositions for producing a chimeric polypeptide
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2018345751A1 (en) * 2017-10-02 2020-05-07 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
CN109120869B (zh) * 2018-11-07 2024-09-06 深圳市道通智能航空技术股份有限公司 双光图像整合方法、整合设备及无人机
AU2019377515A1 (en) * 2018-11-09 2021-05-27 Kiniksa Pharmaceuticals, Gmbh Treatment for giant cell arteritis
US20220331425A1 (en) * 2019-06-03 2022-10-20 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists

Also Published As

Publication number Publication date
AU2021372454A1 (en) 2023-06-22
WO2022093855A1 (en) 2022-05-05
US20220184179A1 (en) 2022-06-16
AU2021372454A9 (en) 2024-09-12
JP2023546657A (ja) 2023-11-07
EP4232162A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
KR102662228B1 (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN105451770B (zh) 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
JP7691418B2 (ja) 癌を治療するためのＰＤ－１アンタゴニスト、ＶＥＧＦＲ／ＦＧＦＲ／ＲＥＴチロシンキナーゼ阻害剤、及びＣＢＰ／β－カテニン阻害剤の組合せ
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP2025013608A (ja) Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
US20230131598A1 (en) Combination treatment for cancer
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
KR20230095983A (ko) Gm-csf 길항제를 사용한 암의 치료
US20230149543A1 (en) Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
CN116685352A (zh) 用gm-csf拮抗剂治疗癌症
RU2838452C1 (ru) Комбинация антагониста pd-1, ингибитора тирозинкиназы vegfr/fgfr/ret и ингибитора cbp/бета-катенина для лечения рака
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
HK40109234A (zh) 用於治疗癌症的方法和组合物
HK40110052A (zh) 用於治疗癌症的方法和组合物
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230511

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241024

Comment text: Request for Examination of Application